NO20056131L - En farmasoytisk sammensetning som innbefatter en P2X7-reseptorantagonist og en tumornekrosefaktor alfa - Google Patents

En farmasoytisk sammensetning som innbefatter en P2X7-reseptorantagonist og en tumornekrosefaktor alfa

Info

Publication number
NO20056131L
NO20056131L NO20056131A NO20056131A NO20056131L NO 20056131 L NO20056131 L NO 20056131L NO 20056131 A NO20056131 A NO 20056131A NO 20056131 A NO20056131 A NO 20056131A NO 20056131 L NO20056131 L NO 20056131L
Authority
NO
Norway
Prior art keywords
receptor antagonist
necrosis factor
tumor necrosis
pharmaceutical composition
factor alpha
Prior art date
Application number
NO20056131A
Other languages
English (en)
Norwegian (no)
Inventor
Nigel Boughton-Smith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312321A external-priority patent/GB0312321D0/en
Priority claimed from SE0301655A external-priority patent/SE0301655D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20056131L publication Critical patent/NO20056131L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20056131A 2003-05-29 2005-12-22 En farmasoytisk sammensetning som innbefatter en P2X7-reseptorantagonist og en tumornekrosefaktor alfa NO20056131L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312321A GB0312321D0 (en) 2003-05-29 2003-05-29 New combination
SE0301655A SE0301655D0 (sv) 2003-06-05 2003-06-05 New combination
PCT/SE2004/000817 WO2004105798A1 (en) 2003-05-29 2004-05-27 A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α

Publications (1)

Publication Number Publication Date
NO20056131L true NO20056131L (no) 2006-02-28

Family

ID=33492248

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056131A NO20056131L (no) 2003-05-29 2005-12-22 En farmasoytisk sammensetning som innbefatter en P2X7-reseptorantagonist og en tumornekrosefaktor alfa

Country Status (15)

Country Link
US (1) US20070032465A1 (es)
EP (1) EP1633401A1 (es)
JP (1) JP2007501270A (es)
KR (1) KR20060037258A (es)
AR (1) AR044452A1 (es)
BR (1) BRPI0410739A (es)
CA (1) CA2526883A1 (es)
CO (1) CO5640094A2 (es)
IS (1) IS8188A (es)
MX (1) MXPA05012705A (es)
NO (1) NO20056131L (es)
RU (1) RU2350354C2 (es)
TW (1) TW200507829A (es)
UY (1) UY28335A1 (es)
WO (1) WO2004105798A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US20090042832A1 (en) * 2005-03-07 2009-02-12 Ganga Raju Gokaraju Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
EA201290876A1 (ru) 2010-03-05 2013-03-29 Президент Энд Феллоуз Оф Гарвард Колледж Композиции индуцированных дендритных клеток и их использование
US10444122B2 (en) 2010-04-01 2019-10-15 Agri-Labs Holdings Llc Soil sample tracking system and method
US9538710B2 (en) 2010-04-01 2017-01-10 Tony Wayne Covely Crop product tracking system and method
CN103841969A (zh) * 2011-08-04 2014-06-04 美国卫生和人力服务部 经由药物介导的对类二十烷酸平衡的操作治疗和预防微生物介导的疾病
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
KR102035463B1 (ko) * 2018-02-14 2019-11-26 연세대학교 산학협력단 암 줄기세포의 치료용 약학 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
KR20000065219A (ko) * 1996-05-20 2000-11-06 마르크 젠너 티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
NZ514477A (en) * 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
JP4523273B2 (ja) * 2001-07-02 2010-08-11 ナームローゼ・フエンノートチヤツプ・オルガノン テトラヒドロキノリン誘導体
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
TW200507829A (en) 2005-03-01
CO5640094A2 (es) 2006-05-31
RU2005136131A (ru) 2006-07-27
EP1633401A1 (en) 2006-03-15
RU2350354C2 (ru) 2009-03-27
BRPI0410739A (pt) 2006-06-27
IS8188A (is) 2005-12-20
KR20060037258A (ko) 2006-05-03
US20070032465A1 (en) 2007-02-08
JP2007501270A (ja) 2007-01-25
MXPA05012705A (es) 2006-02-08
AU2004243137A1 (en) 2004-12-09
UY28335A1 (es) 2004-12-31
AR044452A1 (es) 2005-09-14
WO2004105798A1 (en) 2004-12-09
CA2526883A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
NO20056131L (no) En farmasoytisk sammensetning som innbefatter en P2X7-reseptorantagonist og en tumornekrosefaktor alfa
NO20061662L (no) Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament
NO20062508L (no) Administrering av levodopa og karbidopa
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
CY1115386T1 (el) Συνδυασμος αζελαστινης και μομεταζονης
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
ATE427747T1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
TNSN03137A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
GEP20094601B (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
SE9800836D0 (sv) New Compounds
EA200501586A1 (ru) Фармацевтические продукты
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
NO20014986L (no) 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
WO2006002057A3 (en) Treatment of acne
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
HUP0401854A2 (hu) COX-2 inhibitorokat és aszpirint tartalmazó kombinációk
NO20080035L (no) Benzooksazol-2-on derivater som lipase og fosfolipaseinhibitorer
NO20061514L (no) Farmasoytisk formulering omfattende et pyrimidin-A-onderivat belagt med en enterisk polymer og fremgangsmate for fremstilling derav
Oh et al. Capsazepine, a vanilloid receptor antagonist, inhibits the expression of inducible nitric oxide synthase gene in lipopolysaccharide-stimulated RAW264. 7 macrophages through the inactivation of nuclear transcription factor-kappa B
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application